Circulating heart failure biomarkers beyond natriuretic peptides : review from the Biomarker Study Group of the Heart Failure Association (), European Society of Cardiology ()
Meijers, Wouter C. (University Medical Center Groningen, The Netherlands)
Bayés-Genís, Antoni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Mebazaa, Alexandre (Université de Paris)
Bauersachs, Johann (Hannover Medical School, Germany)
Cleland, John G.F. (University of Glasgow)
Coats, Andrew J. S. (University of Warwick, Coventry, UK)
Januzzi, James L. (Massachusetts General Hospital, Boston, USA)
Maisel, Alan S. (University of California, USA)
McDonald, Kenneth (St Vincent's University Hospital, Dublin, Ireland)
Mueller, Thomas (Hospital of Bolzano, Italy)
Richards, A. Mark (National University of Singapore)
Seferovic, Petar (Belgrade University, Serbia)
Mueller, Christian (University of Basel, Switzerland)
de Boer, Rudolf A. (University Medical Center Groningen, The Netherlands)
Universitat Autònoma de Barcelona

Fecha:	2021
Resumen:	New biomarkers are being evaluated for their ability to advance the management of patients with heart failure. Despite a large pool of interesting candidate biomarkers, besides natriuretic peptides virtually none have succeeded in being applied into the clinical setting. In this review, we examine the most promising emerging candidates for clinical assessment and management of patients with heart failure. We discuss high-sensitivity cardiac troponins (Tn), procalcitonin, novel kidney markers, soluble suppression of tumorigenicity 2 (sST2), galectin-3, growth differentiation factor-15 (GDF-15), cluster of differentiation 146 (CD146), neprilysin, adrenomedullin (ADM), and also discuss proteomics and genetic-based risk scores. We focused on guidance and assistance with daily clinical care decision-making. For each biomarker, analytical considerations are discussed, as well as performance regarding diagnosis and prognosis. Furthermore, we discuss potential implementation in clinical algorithms and in ongoing clinical trials.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Biomarkers ; Heart failure ; Cardiac troponin ; Sst2 ; Growth differentiation factor-15 ; Galectin-3 ; Procalcitonin ; Adrenomedullin
Publicado en:	European Journal of Heart Failure, Vol. 23 (october 2021) , p. 1610-1632, ISSN 1879-0844

DOI: 10.1002/ejhf.2346
PMID: 34498368

23 p, 1.2 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados